Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0B5RX
|
||||
| Former ID |
DNC014102
|
||||
| Drug Name |
(E)-1-Adamantan-1-yl-3-quinolin-3-yl-propenone
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [530245] | ||
| Formula |
C22H23NO
|
||||
| Canonical SMILES |
C1C2CC3CC1CC(C2)(C3)C(=O)C=CC4=CC5=CC=CC=C5N=C4
|
||||
| InChI |
1S/C22H23NO/c24-21(22-11-16-7-17(12-22)9-18(8-16)13-22)6-5-15-10-19-3-1-2-4-20(19)23-14-15/h1-6,10,14,16-18H,7-9,11-13H2/b6-5+
|
||||
| InChIKey |
IHMKNCCPYWKVEH-AATRIKPKSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Metabotropic glutamate receptor 5 | Target Info | Inhibitor | [530245] | |
| Metabotropicglutamate receptor 1 | Target Info | Inhibitor | [530245] | ||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Metabotropic glutamate receptor group III pathway | |||||
| Metabotropic glutamate receptor group I pathway | |||||
| Endogenous cannabinoid signalingP00027:Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Endogenous cannabinoid signaling | |||||
| References | |||||